Analysing demand and cost of toric IOLs in hospitals

Article

Study results help shed light on using toric IOLs on corneal astigmatism patients

"We were interested in understanding our patient demographic in greater detail so as to establish the need for toric lens provision. We could then plan its probable cost and implementation," said Dr Muhtaseb, previous consultant ophthalmologist at the Singleton Hospital Abertawe Bro Morgannwg University NHS Trust, Swansea, UK.

Compiling the study

At the time of cataract surgery a toric IOL (Rayner TFlex, UK) was implanted to correct for the corneal astigmatism. "We did not consider analysing wavefront errors or other data," added Dr Muhtaseb, "Our focus was on the main element of a patient's clinical picture that we could treat and that would greatly affect the quality of the surgical outcome."

There were minimal factors affecting the results. Dr Mohammed explained. "All patients were seen in the same department by one of the same four technicians, all using the same model of IOL Master, and all patients had surgery using the same model of phacoemulsification device (Storz Millennium)."

Beneficial to hospitals

The measured corneal astigmatism of the majority of the study group (79.5%) was 1.5 D or less. A little less than a quarter of the patients involved in the study had a corneal astigmatism of 0.5 D or less and only about 6.5% of the patients had a corneal astigmatism of more than 1.5 D. This data will prove useful to hospitals in determining the level of need for toric IOLs and how much it will cost to implement the use of these lenses in this setting.

"The data from this study shouldn't only be confined to NHS practices," according to Dr Muhtaseb. "These findings will also benefit patients being treated in private practice." He noted that further clinical data from a greater patient population and using a dedicated corneal topographer could offer a more clinically 'ideal' situation to this type of study, however, the IOLMaster was used as it is practical and relevant to a real-life scenario for many surgeons. In the future, Dr Muhtaseb would like to proceed with a further study of the clinical outcomes and patient satisfaction after toric IOL implantation.

"We hope, however, that our study has added weight to the currently available literature that supports the use of toric IOLs through demonstrating the need for them," concluded Dr Muhtaseb.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.